COMPANY PROFILE

Chroma Medicine

Explore full profile

New genomic medicine company working on epigenetic editing

Boston, United StatesFounded 2021Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2023

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Chroma Medicine

Chroma Medicine is a pioneering startup in the healthcare sector, specializing in the development of single-dose genomic medicines. The company's innovative approach leverages epigenetics, which is the natural process by which our bodies regulate genes. In simple terms, by changing the shape of chromatin (the material in our cells that carries our DNA), cells can control how genes are expressed. This can lead to lasting changes that continue even when cells divide.

Chroma Medicine is using this natural system to create treatments for various diseases. The company's business model is based on research and development, with the aim of creating a new class of therapeutics that can control gene expression without altering the DNA sequence. This approach could potentially revolutionize the treatment of diseases, opening up a vast new area of genomic therapeutics.

The company operates in the biotechnology market, specifically in the field of genomic medicine. Its clients are likely to be healthcare providers and patients suffering from diseases that could be treated with their innovative therapies.

Chroma Medicine generates revenue through the development and sale of its genomic medicines. As a research-intensive company, it also likely benefits from research grants and investment funding.

The company is also actively seeking to expand its team, indicating a growth-oriented approach and a commitment to advancing the field of genomic medicine.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2021
Headquarters: Boston, United States
Employees: 14
Open positions: None listed
Dealroom signal: 62.8/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 2 companies, latest Dec 2024
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
MERGEROther financing	Dec 2024	$0	—	Nvelop Therapeutics	↗
SERIES BOther financing	Mar 2023	$135M	$540M	Sofinnova Partners · Casdin Capital · ARCH Venture Partners · DCVC	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Chroma Medicine website traffic

Latest recorded traffic for Chroma Medicine is 690 monthly website visits, down 54% over the last three months. Chroma Medicine's team declined 33.3% over the past year.

Latest monthly visits690 3-month web change-54% 1-year team growth-33.3%

Monthly website visitsOct 2022–Jul 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FMFocal MedicalApplying our sophisticated technology platforms to revolutionize the way drugs are delivered to improve patient healthcare outcomes	Cary, United States	Acquired	4	$12M	—
TWTwisterbiotechGene therapies for cancers and autoimmune diseases	Houston, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
ABAelius BiotechContract research company specialising in modelling the aero-digestive tract without the use of animal testing	Newcastle upon Tyne, United Kingdom	Operational
LBLeucid BioNext-generation CAR-T cell therapies for refractory cancers	London, United Kingdom	Operational
VBViaNautis BioPolymer nanoparticle platform for targeted intracellular genetic delivery	Cambridge, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational